Retrospective analysis on the management of metastatic gastric cancer patients. A mono-institutional experience. What happens in clinical practice?

Tumori

Volumn 99, Issue 5, 2013, Pages 583-588

  Monti, Manlio ^a   Foca, Flavia ^a   Casadei Gardini, Andrea ^a   Valgiusti, Martina ^a   Frassineti, Giovanni Luca ^a   Amadori, Dino ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

Clinical practice; Dose reduction; End of life; Metastatic gastric cancer; Outcome research; Second line

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; MITOMYCIN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL PRACTICE; CONTINUOUS INFUSION; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS POTENTIAL; MONOTHERAPY; OVERALL SURVIVAL; PATIENT CARE; RETROSPECTIVE STUDY; STOMACH CANCER; TERMINAL CARE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE MANAGEMENT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; RECURRENCE; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84893492993     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161309900504     Document Type: Article

References (21)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimate of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer, 127: 2893-2917, 2010.
2. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK, ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376: 687-697, 2010.
3. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer, 71: 3813-3818, 1993.
4. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S: Randomized phase III trial of 5-fluorouracil alone versus plus cisplatin versus uracil and tegafur plus mitomycin C in patients with unresectable advanced astric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol, 21: 54-59, 2003.
5. Cunningham D, Okines AF, Ashley S: Capecitabine and oxaliplatin for advanced esophagogastric cancer. New Engl J Med, 362: 858-859, 2010.
6. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol, 10: 1063-1069, 2009.
7. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M: S-1 plus cisplatin vs S-1 alone for first-line treatment of advanced gastric cancer (the SPIRITS trial): a phase III trial. Lancet Oncol, 9: 215-221, 2008.
8. Lee SJ, Earle CC, Weeks JC: Outcomes research in oncology: history, conceptual framework, and trends in the literature. J Natl Cancer Inst, 92: 195-204, 2000.
9. Edge SB, Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC Cancer Staging Manual and the future of TNM. Ann Surg Oncol, 17: 1471-1474, 2010.
10. Krumholz HM: Real-world imperative of outcomes research. J Natl Cancer Inst, 92: 195-204, 2000.
11. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev, 3: CD004064, 2010.
12. Cocconi G, Carlini P, Gamboni A, Gasperoni S, Rodinò C, Zironi S, Bisagni G, Porrozzi S, Cognetti F, Di Costanzo F, Canaletti R, Ruggeri EM, Camisa R, Pucci F; Italian Oncology Group for Clinical Research: Cisplatinum, epirubicin, leucovorin and 5 fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol, 14: 1258-1263, 2003.
13. Cullinan SA, Moertel CG, Wieland HS, O'Connell MJ, Poon MA, Krook JE, Mailliard JA, Tschetter LK: Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol, 12: 412-416, 1994.
14. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/ infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol, 28: 1547-1553, 2010.
15. Catalano V, Graziano F, Santini D, D'Emidio S, Baldelli AM, Rossi D, Vincenzi B, Giordani P, Alessandroni P, Testa E, Tonini G, Catalano G: Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer, 99: 1402-1407, 2008.
16. Kang JH, Lee SI, Lim do H, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH: Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol, 30: 1513-1518, 2012.
17. Lin SZ, Tong HF, You T, Yu YJ, Wu WJ, Chen C, Zhang W, Ye B, Li CM, Zhen, ZQ, Xu JRX, Zhou JL: Palliative gastrectomy and chemotherapy for stage IV gastric cancer. J Cancer Res Clin Oncol, 134; 187-192, 2008.
18. Barchielli A, Amorosi A, Balzi D, Crocetti E, Nesi G: Longterm prognosis of gastric cancer in a European country: a population-based study in Florence (Italy). 10-year survival of cases diagnosed in 1985-1987. Eur J Cancer, 37: 1674-1680, 2001.
19. Andreis F, Rizzi A, Rota L, Meriggi F, Mazzocchi M, Zaniboni A: Chemotherapy use at the end of life. A retrospective single centre experience analysis. Chemotherapy use at the end of life. A retrospective single centre experience analysis. Tumori, 97: 30-34, 2011.
20. Martoni AA, Tannenberger S, Mutri V: Cancer chemotherapy near the end of life: the time has come to set guidelines for its appropriate use. Tumori, 93: 417-422, 2007.
21. Hartgrink HH, Putter H, Klein Kranenbarg E, Bonenkamp JJ, van de Velde CJ; Dutch Gastric Cancer Group: Value of palliative resection in gastric cancer. Br J Surg, 89: 1438-1443, 2002.